Physician profile
Leonard Silverstein
NPI 1639138571
$25,270.88
in general payments reported to CMS, 2019-2025
38 companies · $3,357 in 2025
The $3,357 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $954 · 2021: $1,318 · 2022: $2,046 · 2023: $2,009 · 2024: $14K · 2025: $3,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,261 · Food and Beverage: $8,523 · Travel and Lodging: $1,724 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,260.78 |
| Food and Beverage | $8,522.84 |
| Travel and Lodging | $1,724.11 |
| Education | $164.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $7,396.80 | 2023-2024 | Ryaltris |
| Genentech USA, INC. | $4,940.65 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $2,393.62 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,324.83 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,665.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,007.20 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $645.67 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $520.22 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $472.88 | 2025 | Neffy |
| Kaleo, INC. | $447.99 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $396.77 | 2023-2025 | |
| Galderma Laboratories, L.P. | $381.33 | 2024-2025 | Nemluvio |
| Optinose US, INC. | $329.03 | 2019-2025 | |
| Amgen INC. | $308.82 | 2021-2025 | Tezspire |
| Abbvie INC. | $248.06 | 2022-2024 | Rinvoq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.